We're Not Very Worried About Helixmith's (KOSDAQ:084990) Cash Burn Rate
Mar 27
Have your own idea? Try our Stock Screener
South Korean (KOSPI) Biotech Industry Analysis
UpdatedApr 03, 2026
DataAggregated Company Financials
Companies123
- 7D-8.0%
- 3M-8.1%
- 1Y33.6%
- YTDn/a
Over the last 7 days, the Biotech industry has dropped 8.0%, driven by declines in Celltrion and Kolon TissueGene of 5.0% and 21%, respectively. In contrast, ROKIT Healthcare has gained 15%. In the past year, the industry has gained 34%. Looking forward, earnings are forecast to grow by 51% annually.
Industry Valuation and Performance
Has the South Korean Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 03 Apr 2026 | ₩156.0t | ₩16.7t | -₩583,148,769,554.00 | 32.6x | -267.4x | 9.3x |
| Sun, 01 Mar 2026 | ₩183.2t | ₩13.1t | ₩203.8b | 24x | 898.9x | 13.9x |
| Tue, 27 Jan 2026 | ₩175.2t | ₩13.1t | ₩205.3b | 22.9x | 853.5x | 13.4x |
| Thu, 25 Dec 2025 | ₩159.7t | ₩13.1t | ₩224.5b | 22.7x | 711.5x | 12.2x |
| Sat, 22 Nov 2025 | ₩140.8t | ₩12.7t | ₩277.4b | 21.2x | 507.6x | 11.1x |
| Mon, 20 Oct 2025 | ₩118.2t | ₩12.4t | -₩30,278,124,823.00 | 26.5x | -3905.3x | 9.5x |
| Wed, 17 Sep 2025 | ₩122.1t | ₩12.4t | -₩90,788,167,718.00 | 28.9x | -1344.8x | 9.8x |
| Fri, 15 Aug 2025 | ₩113.8t | ₩11.9t | -₩206,923,034,443.00 | 22.6x | -549.9x | 9.5x |
| Sun, 13 Jul 2025 | ₩113.0t | ₩11.8t | -₩203,565,713,503.00 | 24.3x | -555.3x | 9.6x |
| Tue, 10 Jun 2025 | ₩103.8t | ₩11.8t | -₩99,336,020,661.00 | 25.3x | -1044.5x | 8.8x |
| Thu, 08 May 2025 | ₩95.8t | ₩11.4t | -₩456,504,996,975.00 | 28.2x | -209.8x | 8.4x |
| Sat, 05 Apr 2025 | ₩96.8t | ₩11.4t | -₩488,437,240,096.00 | 27x | -198.2x | 8.5x |
| Mon, 03 Mar 2025 | ₩99.5t | ₩10.6t | -₩927,517,473,361.00 | 23.6x | -107.3x | 9.4x |
| Wed, 29 Jan 2025 | ₩93.8t | ₩10.5t | -₩1,004,347,149,181.00 | 23.1x | -93.4x | 9x |
| Fri, 27 Dec 2024 | ₩91.9t | ₩10.5t | -₩1,004,347,149,181.00 | 25.3x | -91.5x | 8.8x |
| Sun, 24 Nov 2024 | ₩84.8t | ₩10.4t | -₩938,134,898,568.00 | 22.7x | -90.4x | 8.1x |
| Tue, 22 Oct 2024 | ₩99.7t | ₩10.3t | -₩653,791,712,887.00 | 28.8x | -152.5x | 9.7x |
| Thu, 19 Sep 2024 | ₩92.4t | ₩9.9t | -₩452,102,902,447.00 | 25.1x | -204.5x | 9.4x |
| Sat, 17 Aug 2024 | ₩94.3t | ₩9.9t | -₩642,636,794,928.00 | 27.9x | -146.7x | 9.6x |
| Mon, 15 Jul 2024 | ₩88.2t | ₩9.9t | -₩651,620,427,048.00 | 23.2x | -135.4x | 8.9x |
| Wed, 12 Jun 2024 | ₩84.9t | ₩9.9t | -₩635,976,480,448.00 | 20.7x | -133.6x | 8.6x |
| Fri, 10 May 2024 | ₩82.0t | ₩9.6t | -₩567,818,034,968.00 | 22.7x | -144.5x | 8.5x |
| Sun, 07 Apr 2024 | ₩78.8t | ₩9.6t | -₩665,568,465,312.00 | 20x | -118.5x | 8.2x |
| Tue, 05 Mar 2024 | ₩78.0t | ₩9.7t | -₩534,696,541,747.00 | 58x | -145.9x | 8x |
| Thu, 01 Feb 2024 | ₩73.0t | ₩9.7t | -₩537,261,689,777.00 | 62.6x | -135.9x | 7.5x |
| Sat, 30 Dec 2023 | ₩67.9t | ₩10.1t | -₩324,278,048,367.00 | 29.3x | -209.3x | 6.7x |
| Mon, 27 Nov 2023 | ₩58.7t | ₩10.1t | -₩315,312,804,519.00 | 25.9x | -186.2x | 5.8x |
| Wed, 25 Oct 2023 | ₩52.8t | ₩10.2t | -₩239,053,318,689.00 | 28.7x | -220.9x | 5.2x |
| Fri, 22 Sep 2023 | ₩56.7t | ₩10.2t | -₩239,053,318,689.00 | 29.3x | -237x | 5.6x |
| Sun, 20 Aug 2023 | ₩57.5t | ₩10.2t | -₩213,622,992,279.00 | 36.2x | -269.1x | 5.6x |
| Tue, 18 Jul 2023 | ₩57.0t | ₩10.3t | -₩151,534,704,579.00 | 26.5x | -376.2x | 5.6x |
| Thu, 15 Jun 2023 | ₩61.1t | ₩10.3t | -₩151,534,704,579.00 | 27.8x | -403.1x | 6x |
| Sat, 13 May 2023 | ₩61.2t | ₩11.0t | ₩317.8b | 26.5x | 192.5x | 5.6x |
| Mon, 10 Apr 2023 | ₩62.0t | ₩11.0t | ₩318.9b | 24.5x | 194.4x | 5.6x |
Price to Earnings Ratio
194.4x
Current Industry PE
- Investors are relatively neutral on the South Korean Biotechnology industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 8.5x.
Past Earnings Growth
- Total earnings for the Biotechnology industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have grown 15% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does South Korean Biotech compare with similar industries?
| KR Market | -4.48% | |
| Healthcare | -8.47% | |
| Biotech | -7.99% | |
| Biotech | -7.99% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A376900 ROKIT Healthcare | ₩142.00k | 14.5% +₩283.3b | n/a | PS85.1x | |
| A127120 JS Link | ₩41.15k | 8.7% +₩112.6b | 489.5% | PS72.7x | |
| A084990 Helixmith | ₩8.88k | 10.9% +₩40.1b | 275.5% | PS157.4x | |
| A382150 Oncocross | ₩7.75k | 15.0% +₩12.3b | -19.6% | PS255.1x | |
| A180400 Dx & Vx | ₩4.81k | 2.2% +₩10.3b | 175.3% | PS16.1x |